These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 28198005)

  • 1. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
    Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
    Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
    Sridharan K; Sivaramakrishnan G
    J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
    Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
    Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin pharmacogenetics.
    Johnson JA; Cavallari LH
    Trends Cardiovasc Med; 2015 Jan; 25(1):33-41. PubMed ID: 25282448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of Warfarin in a Diverse Patient Population.
    Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients.
    Sasano M; Ohno M; Fukuda Y; Nonen S; Hirobe S; Maeda S; Miwa Y; Yokoyama J; Nakayama H; Miyagawa S; Sawa Y; Fujio Y; Maeda M
    Eur J Clin Pharmacol; 2019 Jul; 75(7):901-911. PubMed ID: 30852642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
    Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
    Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race influences warfarin dose changes associated with genetic factors.
    Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
    Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.
    Wattanachai N; Kaewmoongkun S; Pussadhamma B; Makarawate P; Wongvipaporn C; Kiatchoosakun S; Vannaprasaht S; Tassaneeyakul W
    Eur J Clin Pharmacol; 2017 Aug; 73(8):973-980. PubMed ID: 28550460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Biss T; Kamali F; Vear SI; Ho RH; Bajolle F; Loriot MA; Shaw K; Carleton BC; Hamberg AK; Wadelius M; Hirono K; Taguchi M; Wakamiya T; Yanagimachi M; Hirai K; Itoh K; Brandão LR; Ito S
    Pharmacogenomics J; 2020 Apr; 20(2):306-319. PubMed ID: 31673144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance.
    Shahabi P; Scheinfeldt LB; Lynch DE; Schmidlen TJ; Perreault S; Keller MA; Kasper R; Wawak L; Jarvis JP; Gerry NP; Gordon ES; Christman MF; Dubé MP; Gharani N
    Thromb Haemost; 2016 Aug; 116(2):337-48. PubMed ID: 27121899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.
    Kocael A; Eronat AP; Tüzüner MB; Ekmekçi A; Orhan AL; İkizceli İ; Yılmaz-Aydoğan H; Öztürk O
    Mol Biol Rep; 2019 Apr; 46(2):1825-1833. PubMed ID: 30712247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
    Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
    Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.
    Mazzaccara C; Conti V; Liguori R; Simeon V; Toriello M; Severini A; Perricone C; Meccariello A; Meccariello P; Vitale DF; Filippelli A; Sacchetti L
    PLoS One; 2013; 8(8):e71505. PubMed ID: 23990957
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.